FLASH Irradiation Results in Reduced Severe Skin Toxicity Compared to Conventional-Dose-Rate Irradiation.
Journal
Radiation research
ISSN: 1938-5404
Titre abrégé: Radiat Res
Pays: United States
ID NLM: 0401245
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
27
03
2020
accepted:
18
06
2020
pubmed:
28
8
2020
medline:
9
3
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
Radiation therapy, along with surgery and chemotherapy, is one of the main treatments for cancer. While radiotherapy is highly effective in the treatment of localized tumors, its main limitation is its toxicity to normal tissue. Previous preclinical studies have reported that ultra-high dose-rate (FLASH) irradiation results in reduced toxicity to normal tissues while controlling tumor growth to a similar extent relative to conventional-dose-rate (CONV) irradiation. To our knowledge this is the first report of a dose-response study in mice comparing the effect of FLASH irradiation vs. CONV irradiation on skin toxicity. We found that FLASH irradiation results in both a lower incidence and lower severity of skin ulceration than CONV irradiation 8 weeks after single-fraction hemithoracic irradiation at high doses (30 and 40 Gy). Survival was also higher after FLASH hemithoracic irradiation (median survival >180 days at doses of 30 and 40 Gy) compared to CONV irradiation (median survival 100 and 52 days at 30 and 40 Gy, respectively). No ulceration was observed at doses 20 Gy or below in either FLASH or CONV. These results suggest a shifting of the dose-response curve for radiation-induced skin ulceration to the right for FLASH, compared to CONV irradiation, suggesting the potential for an enhanced therapeutic index for radiation therapy of cancer.
Identifiants
pubmed: 32853385
pii: 438396
doi: 10.1667/RADE-20-00090
pmc: PMC7855987
mid: NIHMS1657027
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
618-624Subventions
Organisme : NCI NIH HHS
ID : R01 CA197136
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233958
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009302
Pays : United States
Organisme : NCIRD CDC HHS
ID : U66 IP000443
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
©2020 by Radiation Research Society. All rights of reproduction in any form reserved.
Références
Phys Med Biol. 2019 Sep 11;64(18):185005
pubmed: 31365907
Radiother Oncol. 2019 Oct;139:11-17
pubmed: 31253466
Sci Transl Med. 2014 Jul 16;6(245):245ra93
pubmed: 25031268
Head Neck. 2018 Sep;40(9):2078-2093
pubmed: 29684256
Radiat Res. 2020 Jan;193(1):1-4
pubmed: 31657670
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):195-203
pubmed: 27816362
Clin Oncol (R Coll Radiol). 2019 Jul;31(7):407-415
pubmed: 31010708
Semin Radiat Oncol. 2017 Jul;27(3):218-228
pubmed: 28577829
Radiother Oncol. 2017 Sep;124(3):365-369
pubmed: 28545957
Clin Cancer Res. 2019 Jan 1;25(1):35-42
pubmed: 29875213
Radiother Oncol. 2019 Oct;139:28-33
pubmed: 31178058
Nat Rev Dis Primers. 2019 Feb 21;5(1):13
pubmed: 30792503
Isr Med Assoc J. 2018 Sep;20(9):582-583
pubmed: 30221874
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):539-547
pubmed: 32145319
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):470-9
pubmed: 24686268
Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):190-192
pubmed: 31145965
Radiother Oncol. 2019 Oct;139:18-22
pubmed: 31303340
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):440-448
pubmed: 31928642
Radiother Oncol. 2019 Oct;139:23-27
pubmed: 31010709